Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bryskier

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|January 30, 1999
Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophilsD Vazifeh, A Bryskier, M T Labro
Antimicrobial Agents and Chemotherapy|June 1, 1994
Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complexN Rastogi, K S Goh, A Bryskier
Antimicrobial Agents and Chemotherapy|June 13, 1998
In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in GermanyR R Reinert, A Bryskier, R Lütticken
The Journal of Antimicrobial Chemotherapy|November 1, 1990
Cefodizime, a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology and structure-activity relationshipsA Bryskier, T Procyk, M T Labro
Presse Medicale (Paris, France : 1983)|December 21, 1985
[Therapeutic prospects of new fluoroquinolones]A Bryskier, J F Chantot, P Veyssier
Antimicrobial Agents and Chemotherapy|December 1, 1996
In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampinK P Klugman, T Capper, A Bryskier
The Journal of Antibiotics|May 1, 1986
Antibacterial activity of roxithromycin: a laboratory evaluationJ F Chantot, A Bryskier, J C Gasc
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 7, 2004
Preparation of stock solutions of macrolide and ketolide compounds for antimicrobial susceptibility testsA Barry, A Bryskier, M Traczewski, et al.
Pathologie-Biologie|June 1, 1986
[In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime]P Le Noc, A Bryskier, D Le Noc
The Journal of Antimicrobial Chemotherapy|July 15, 1999
Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacinH B Drugeon, M E Juvin, A Bryskier
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|January 30, 1999
Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophilsD Vazifeh, A Bryskier, M T Labro
Antimicrobial Agents and Chemotherapy|June 1, 1994
Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complexN Rastogi, K S Goh, A Bryskier
Antimicrobial Agents and Chemotherapy|June 13, 1998
In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in GermanyR R Reinert, A Bryskier, R Lütticken
The Journal of Antimicrobial Chemotherapy|November 1, 1990
Cefodizime, a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology and structure-activity relationshipsA Bryskier, T Procyk, M T Labro
Presse Medicale (Paris, France : 1983)|December 21, 1985
[Therapeutic prospects of new fluoroquinolones]A Bryskier, J F Chantot, P Veyssier
Antimicrobial Agents and Chemotherapy|December 1, 1996
In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampinK P Klugman, T Capper, A Bryskier
The Journal of Antibiotics|May 1, 1986
Antibacterial activity of roxithromycin: a laboratory evaluationJ F Chantot, A Bryskier, J C Gasc
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 7, 2004
Preparation of stock solutions of macrolide and ketolide compounds for antimicrobial susceptibility testsA Barry, A Bryskier, M Traczewski, et al.
Pathologie-Biologie|June 1, 1986
[In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime]P Le Noc, A Bryskier, D Le Noc
The Journal of Antimicrobial Chemotherapy|July 15, 1999
Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacinH B Drugeon, M E Juvin, A Bryskier
Pageof 11